Conn Bay (600572.SH): Submitted the US FDA New Drug Marketing Application for Sibopardo

Zhitong Financial App News, Conn Bay (600572.SH) announced that recently, the company submitted a new drug marketing application (NNDA) to the US Food and Drug Administration (FDA) through the introduction of a licensed (license-in) cooperative product, Adneuris Therapeutics, Inc. (“Adneuris” for short, a wholly-owned subsidiary of Tris Pharma, Inc.) to the US Food and Drug Administration (FDA) to treat adults severe acute pain.

Sibopadol is the world's first NOP (nociceptive peptide/orphin receptor) +MOP dual-target oral analgesic. The West Boppard NDA was submitted by Adneuris, an overseas equity holder, to the US FDA. This submission is a key point in overseas registration of this product. Conn Bay has exclusive rights to develop and commercialize all of this product in Greater China. If this product is approved in the US, it will provide an important reference for clinical research, registration, etc. before it is marketed in China.